Bio-Rad Laboratories this week reported a 2 percent increase in its third-quarter revenues, to $471.5 million from $461.1 million in the comparable period of 2009.

Sales for the company's life science segment increased 2 percent to $153.2 million, while clinical diagnostics sales were also up around 2 percent to $314.9 million. Clinical diagnostic sales include $13.6 million from the Biotest business, which Bio-Rad acquired in the first quarter of 2010.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.